Increasing evidence has pointed to activated type I interferon signaling in tumors. However, the molecular basis for such activation and its role in tumorigenesis remain unclear. In the current studies, we report that activation of type I interferon (IFN) signaling in tumor cells is primarily due to elevated secretion of the type I interferon, IFN-β. Studies in oncogene-transformed cells suggest that oncogenes such as Ras and Src can activate IFN-β signaling. Significantly, elevated IFN-β signaling in Ras-transformed mammary epithelial MCF-10A cells was shown to contribute to Ras transformation as evidenced by morphological changes, anchorage-independent growth, and migratory properties. Our results demonstrate for the first time that the type I IFN, IFN-β, contributes to Ras transformation and support the notion that oncogene-induced cytokines play important roles in oncogene transformation.
References
[1]
Wenzel J, Tomiuk S, Zahn S, Küsters D, Vahsen A, et al. (2008) Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. International Journal of Cancer 123: 2605–2615.
[2]
Chi L-M, Lee C-W, Chang K-P, Hao S-P, Lee H-M, et al. (2009) Enhanced Interferon Signaling Pathway in Oral Cancer Revealed by Quantitative Proteome Analysis of Microdissected Specimens Using 16O/18O Labeling and Integrated Two-dimensional LC-ESI-MALDI Tandem MS. Molecular & Cellular Proteomics 8: 1453–1474.
[3]
Andersen JB, Hassel BA (2006) The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: Friend or foe? Cytokine & Growth Factor Reviews 17: 411–421.
[4]
Desai SD, Haas AL, Wood LM, Tsai Y-C, Pestka S, et al. (2006) Elevated Expression of ISG15 in Tumor Cells Interferes with the Ubiquitin/26S Proteasome Pathway. Cancer Research 66: 921–928.
[5]
Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, et al. (2006) Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 94: 1465–1471.
[6]
Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, et al. (2009) Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene 28: 2606–2620.
[7]
Ye H, Yu T, Temam S, Ziober BL, Wang J, et al. (2008) Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics 9: 69.
[8]
Bektas N, Noetzel E, Veeck J, Press M, Kristiansen G, et al. (2008) The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Research 10: R58.
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442–454.
[11]
Campbell PM, Der CJ (2004) Oncogenic Ras and its role in tumor cell invasion and metastasis. Seminars in Cancer Biology 14: 105–114.
[12]
Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000) The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76–83.
[13]
Hajra KM, Ji X, Fearon ER (1999) Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 18: 7274–7279.
[14]
Dorudi S, Hanby AM, Poulsom R, Northover J, Hart IR (1995) Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 71: 614–616.
[15]
Kowalski P, Rubin M, Kleer C (2003) E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 5: 217–222.
[16]
Nguyen KT, Wang WJ, Chan JL, Wang LH (2000) Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells. Oncogene 19: 5385–5397.
[17]
Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR (1996) MCF1 OAT: A Model for the Evolution of Cancer from Proliferative Breast Disease. Am J Pathol 148: 313–319.
[18]
Lenardo MJ, Fan C-M, Maniatis T, Baltimore D (1989) The involvement of NF-[kappa]B in [beta]-interferon gene regulation reveals its role as widely inducible mediator of signal transduction. Cell 57: 287–294.
[19]
Vinas-Castells R, Beltran M, Valls G, Gomez I, Garcia JM, et al. (2010) The Hypoxia-controlled FBXL14 Ubiquitin Ligase Targets SNAIL1 for Proteasome Degradation. Journal of Biological Chemistry 285: 3794–3805.
[20]
Nielsch U, Pine R, Zimmer SG, Babiss LE (1992) Induced expression of the endogenous beta interferon gene in adenovirus type 5-transformed rat fibroblasts. J Virol 66: 1884–1890.
[21]
Sarkar SN, Peters KL, Elco CP, Sakamoto S, Pal S, et al. (2004) Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat Struct Mol Biol 11: 1060–1067.
[22]
Sizemore N, Leung S, Stark GR (1999) Activation of Phosphatidylinositol 3-Kinase in Response to Interleukin-1 Leads to Phosphorylation and Activation of the NF-kappa B p65/RelA Subunit. Mol Cell Biol 19: 4798–4805.
[23]
Karin M, Greten FR (2005) NF-[kappa]B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749–759.
[24]
MacDonald NJ, Kuhl D, Maguire D, N？f D, Gallant P, et al. (1990) Different pathways mediate virus inducibility of the human IFN-[alpha]1 and IFN-[beta] genes. Cell 60: 767–779.
[25]
Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, et al. (1993) Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proceedings of the National Academy of Sciences of the United States of America 90: 10193–10197.
[26]
Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6: 447–458.
[27]
Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, et al. (2009) IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer. Cancer Cell 15: 103–113.
[28]
Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, et al. (1991) IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. The Journal of Immunology 147: 4402–4407.
[29]
Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunological Reviews 202: 8–32.
[30]
Ludwig CU, Durie BGM, Salmon SE, Moon TE (1983) Tumor growth stimulation in vitro by interferons. European Journal of Cancer and Clinical Oncology 19: 1625–1632.
[31]
da Silva AJ, Brickelmaier M, Majeau GR, Lukashin AV, Peyman J, et al. (2002) Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res 22: 173–188.
[32]
Yong VW, Chabot S, Stuve O, Williams G (1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51: 682–689.
[33]
Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195: 346–355.
[34]
Keydar I, Chen L, Karby S, Weiss FR, Delarea J, et al. (1979) Establishment and characterization of a cell line of human breast carcinoma origin. European Journal of Cancer (1965) 15: 659–670.
[35]
Rubinstein S, Familletti PC, Pestka S (1981) Convenient assay for interferons. J Virol 37: 755–758.
